tirzepatide surpass-4 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial New SURPASS-CVOT Ad Hoc Analysis:

Single and dual agonists The fundamental difference between these two molecules is that semaglutide is a GLP-1 agonist, i.e., it has a strong structural similarity (95%) with this hormone and specifically activates its receptor, while tirzepatide is a dual agonist, i.e., it has a hybrid structure that allows it to activate both GLP-1 and GIP receptors (Figure 2)

Scientists may glean more hints in future tirzepatide trials

It is also one of the reasons that peptide formulations are typically buffered at slightly acidic pH, where deamidation is slower

RESULTS Of the patients who switched from 1.0 mg of semaglutide to tirzepatide, 10 received a maintenance dose of 7.5 mg and five received 10 mg

Read more about tirzepatide shelf life in the fridge